The IRCM
Research
The Clinic
Studying at IRCM
Core facilities
Conferences
Careers
Biochemical Neuroendocrinology
Skip navigation links
Director
Team
Projects
Publications
Conferences
Available positions
Contact us


Publications

Selected publications

2013

  1. Jänis M.T., Tarasov, K., Ta H. X., Ekroos, K., Hurme R., Kleber M.E., März W., Prat A., Seidah N.G.,, Laaksonen R. The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Deficiency Causes Significant Decreases In Plasma Sphingolipids In Mouse And Man. Atherosclerosis (in press) [IF=4.0]
  2. Guillemot J and Seidah N.G. The proprotein convertase PC7 sheds the human TfR1 independent of HFE. Hepatology (in press) [IF=11.7] PMID: 23505014
  3. Berthold H.K., Seidah N.G., Benjannet S., and Gouni-Berthold I. Simvastatin but not Ezetimibe Increases the Levels of Circulating PCSK9: A Randomized Study. PLoS One. 2013;8(3):e60095 [IF=4.4] PMID: 23544125
  4. Guillemot J., Canuel M., Essalmani R., Prat A., and Seidah N.G. The proprotein convertase PC7 is the sheddase of human transferrin receptor 1: implication in iron homeostasis. Hepatology (in press) PMID: 23390091 [IF=11.7]
  5. Poirier S., Mayer G., Murphy S.R., Garver W.S., Chang T.Y., Schu O., and Seidah N.G. The cytosolic adaptor AP-1A is essential for the trafficking and function of Niemann-Pick type C proteins. Traffic 14:458-469, 2013 PMID: 23350547 [IF=6.3]
  6. Seidah N.G. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholes-terolemia and other pathologies. Current Pharmaceutical Design), 2013 PMID:23317404 [IF=4.8]
  7. Levy E., Ouadda A.B., Spahis S., Sane A.T., Garofalo C., Grenier E., Emonnot L., Yara S., Couture P., Beaulieu J.F., Ménard D., Seidah N.G., Elchebly M. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 227(2):297-306, 2013 PMID: 23422832 [4.0]


2012

  1. Sun X., Essalmani R., Day R., Khatib A-M., Seidah N.G., and Prat A. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia 14:1122-1131, 2012 PMID: 23308045 [IF=5.1]
  2. Luna S.Y.G., Day R., and Seidah N.G. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. J. Biol. Chem. 287:43492-43501, 2012 PMID: 23105118 [IF=5.8]
  3. Besnard J., Ruda G.P., Setola V., Abecassis K., Rodriguez R.M., Huang X-P., Norval S., Sassano M.F., Shin A.I., Webster L.A., Simeons F.R.C., Stojanovski L., Prat A., Seidah N.G., Constam D.B., Bickerton G.R., Read K.D., Wetsel W.C., Gilbert I.H., Roth B.L., and Hopkins A.L. Adaptive design of ligands with polypharmacology profiles. Nature 492:215-220, 2012  PMID: 23235874 [IF=36.3]
  4. Maret D., Seyed Sadr M., Seyed Sadr E., Colman D.R., Del Maestro R.F., and Seidah N.G. Opposite Roles of Furin and PC5A in N-Cadherin Processing. Neoplasia 14:880-892, 2012 PMID: 23097623 [IF=5.1]
  5. Benjannet S., Hamelin J., Chrétien M., and Seidah N.G. Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects and LDLR degradation. J. Biol. Chem. 287:33745-33755, 2012 PMID: 22875854 [IF=5.8]
  6. Fantus D., Awan Z., Seidah N.G., and Genest J. Aortic Calcifications: Novel Insights from Familial Hypercholesterolemia and Potential Role for the Low-Density Lipoprotein Receptor. Atherosclerosis pii: S0021-9150(12)00575-8, 2012 PMID:23040868 [IF=4.0]
  7. Seidah N.G., Poirier S., Denis M., Parker R., Prat A., Wassef H., Davignon J., Hajjar K.A., Mayer G. Annexin A2 is an extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One 7:e41865, 2012 PMID: 22848640 [IF=4.4]
  8. Kim W.J., Essalmani R., Szumska D., Creemers J.W.M., Roebroek A.J.M., D’Orleans-Juste P., Bhattacharya S., Seidah N.G., Prat A. Loss of endothelial furin leads to cardiac malformation and early postnatal death Mol. Cell. Biol  32:3382-3391, 2012 PMID: 22733989  [IF=6.2]
  9. Blanchet M., Seidah N.G. , and Labonté P. SKI-1/S1P inhibition: a promising surrogate to statins to block Hepatitis C virus replication. Antiviral Res. 95:159-166, 2012 [IF=4.4]
  10. Abifadel M., Guerin M., Benjannet S., Rabès J-P., Le Goff W., Julia Z., Hamelin J., Carreau V., Varret M., Bruckert E., Tosolini L., Meillhac O., Couvert P., Bonnefont-Rousselot D., Chapman J., Carrié A., Michel J-B., Prat A., Seidah N.G., Boileau C. Identification and characterization of new gain of function mutations in the PCSK9 gene responsible for Autosomal Dominant Hypercholesterolemia. Atherosclerosis 223:394-400, 2012 PMID: 22683120 [IF=4.0]
  11. Seidah N.G. and Prat A. The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery 11:367-383, 2012 [IF=28.7]
  12. Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., Seidah N.G., Prat A. Gene inactivation of PCSK9 reduces atherosclerosis in mice. Circulation 21:894-901, 2012  [IF=14.6]
  13. Rousselet E., Kriz J., Seidah N.G. Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining. J Vis Exp. 69 DOI:pii: 4038, 2012 [IF=1.2]
  14. Awan Z., Seidah N.G., MacFadyen. J.G., Benjannet S., Chasman D.I., Ridker P.M., Genest J. Rosuvastatin, PCSK9 Levels, and LDL-C Response: The JUPITER Trial. Clin Chem. 58:183-189, 2012 [IF=6.2]


2011
 

  1. Awan Z., Seidah N.G., JMacFadyen.G., Benjannet S., Chasman D.I., Ridker P.M., Genest J. Rosuvastatin, PCSK9 Levels, and LDL-C Response: The JUPITER Trial. Clin. Chem. (in press), 2011 [IF=6.2]
  2. Awan Z., Denis M., Bailey D., Prat A., Goltzman D., Seidah N.G., Genest J. The LDLR Deficient Mouse as a Model for Aortic Calcification and Quantification by Micro Computed Tomography. Atherosclerosis  (in press), 2011 [IF=4.5]
  3. Mayne J., Dewpura T., Raymond A., Bernier L., Cousins M., Ooi T.C., Davignon J., Seidah N.G., Mbikay M. and Chrétien M. A Novel Loss of Function PCSK9 Mutation in a French-Canadian Family Exhibits a Dominant Negative Effect on Cholesterolemia. Clin. Chem. 10:1415-1423, 2011 [IF=6.2]
  4. Prat A., Behrendtb M., Marcinkiewicz E., Boridy S., Sairam M.R., Seidah N.G., and Maysinger D. Chronic estrogen deficiency leads to glial cell activation and hypertrophy in a novel mouse model of Alzheimer’s disease (AD). J. Aging Res. 2011:251517-251529, 2011
  5. Sun X., Essalmani R., Susan-Resiga D., Prat A. and Seidah N.G. Latent TGFb binding protein-2 and -3 inhibit the proprotein convertase 5/6A. J. Biol. Chem. 286: 29063-29073, 2011 [IF=5.8]
  6. Marchesi C., Essalmani R., Leibovitz E., Ebrahimian T., Paradis P., Seidah N.G., Schiffrin E.L., and Prat A. Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med (Berl). 89 :1103-1111, 2011 [IF 5.9]
  7. Richard C., Couture P., Desroches S., Benjannet S., Seidah N.G., Lichtenstein A., and Lamarche B.: Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. British J. Nutrition 26:1-7, 2011 [IF=3.5]
  8. Susan-Resiga D., Essalmani R., Hamelin J., Asselin M-C., Benjannet S., Chamberland A., Day R., Szumska D., Constam D., Bhattacharya S., Prat A., Seidah N.G. Furin is the major processing enzyme of the cardiac-specific growth factor BMP10. J Biol Chem. 286:22785-22794,  2011 [IF=5.8]
  9. Pasquato A., Burri D.J., Gomez-Ibarlucea Traba E., Hanna-El-Daher L., Seidah N.G.  and Kunz S. . Arenavirus envelope glycoproteins mimic autoprocessing sites of the cellular proprotein convertase subtilisin kexin isozyme-1/site-1 protease. Virology 417:18-26, 2011 [IF=3.2]
  10. Rousselet E., Marcinkiewicz J., Kriz J., Zhou A., Hatten M.E., Prat A., Seidah N.G. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res. 52:1383-1391, 2011 [IF=4.4]
  11. Zandberg W.F., Benjannet, S., Hamelin J. Pinto, B.M., Seidah N.G.  N-Glycosylation controls trafficking, zymogen activation, and substrate processing of proprotein convertases PC1/3 and SKI-1. Glycobiology 10:1290-1300, 2011 [IF=3.9]
  12. Denis N., Elisma F., Palmer-Smith H., Busuttil A., Wright T., Bou Khalil M, Prat A., Seidah N.G., Chrétien M., Mayne J., and Figeys D. Quantitative Proteomic Analysis of PCSK9 Gain of Function in Hepatic HuH7 Cells. J Proteome Res. 10:2011-2026, 2011 [IF=5.4]
  13. Seidah N.G. The proprotein convertase PCSK9. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  14. Seidah N.G. The proprotein convertase SKI-1/S1P. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  15. Seidah N.G. The proprotein convertase PC7. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  16. Seidah N.G. The proprotein convertase PC5/6. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  17. Seidah N.G. The proprotein convertase PC4. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  18. Seidah N.G. The proprotein convertase PC2. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  19. Seidah N.G. The proprotein convertase PC1/3. Book Chapter in Handbook of Proteolytic Enzymes. 2011 (in press)
  20. Seidah N.G., The Proprotein Convertases., 20 years later. Methods in Molecular Biology 768: 23-57, 2011 [IF=3.7]
  21. Rousselet E., Benjannet S., Marcinkiewicz E., Asselin M.-C., Lazure C., and Seidah N.G. The Proprotein Convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor. J Biol Chem. 286:9185-95, 2011 [IF=5.8]
  22. Seidah N.G. What lays ahead for the proprotein convertases? From fundamental research to translational applications. Annals of the New York Academy of Sciences 1220: 149-161, 2011 [IF=2.7]
  23. Essalmani R., Susan-Resiga D. , Chamberland A., Abifadel M., Creemers J.W. , Boileau C., Seidah N.G., and Prat A. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem. 286: 4257-63, 2011 [IF=5.8]
  24. Tremblay A.J., Lamarche B, Lemelin V., Gagnon P., Trelles F., Benjannet S., Seidah N.G., Davis H.R. Jr., and Couture P.: Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J. Lipid Res. 52: 558-565, 2011 [IF=4.4]
  25. Roubtsova A.S., Munkonda M-N., Awan Z., Marcinkiewicz J., Chamberland A., Lazure C., Cianflone K., Seidah N.G., and Prat A. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 4:785-791, 2011 [IF=7.2]
  26. Rousselet E., Benjannet S., Hamelin J., Canuel M., and Seidah N.G. The proprotein convertase PC7: unique zymogen activation and trafficking pathways. J. Biol. Chem. 286: 2728-2738, 2011 [IF=5.8]
  27. Gorski J.P., Huffman N T., Chittur S, Midura R J., Black D, Oxford J, and Seidah N.G.: Inhibition of the proprotein convertase SKI-1 and caspase-3 blocks transcription of key extracellular matrix genes regulating osteoblastic mineralization. J. Biol. Chem. 286: 1836-1849, 2011 [IF=5.8] 


2010 

  1. Benjannet S., Luna G., Hamelin J., Pasquato A., Duclos F.J., Parker R., Mayer G., and Seidah N.G. Effects of the prosegment and pH on the activity of PCSK9: evidence for an additional processing event. J. Biol. Chem. 285: 40965-40978, 2010  [IF=5.8]
  2. Maret D., Gruzglin E., Sadr M.S., Siu V., Shan W., Koch A.W., Seidah N.G., Del Maestro R.F., and Colman D.R. Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia 12:1066-1680, 2010. [IF=5.1]
  3. Chitramuthu B.P., Baranowski D., Cadieux B , Seidah N.G. and Bennett H.P.J. Molecular cloning and embryonic expression of zebrafish PCSK5/6 co-orthologues; Functional assessment during lateral line development. Developmental Dynamics 239:2933–2946, 2010 [IF=3.1]
  4. Davignon J., Dubuc G., and Seidah N.G. The Influence of PCSK9 Polymorphisms on Serum LDL Cholesterol and Risk of Atherosclerosis. Current Atherosclerosis Reports. 12: 308-315, 2010 [IF=3.0]
  5. Khatib A-M., Lahlil R., Scamuffa N., Akimenko M-A., Ernest S, Lomri A., Lalou C., Seidah N.G., Villoutreix B., Calvo F. Zebrafish ProVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed ProVEGF-C during fin regeneration.PLoS One 5: e11438, 2010 [IF=4.4]
  6. Gupta N., Fisker N., Asselin M.-C., Lindholm M., Rosenbohm C., Ørum H., Elmén J., Seidah N.G., and Straarup E. M. A locked nucleic acid antisense oligonucleotide silences PCSK9 and enhances LDLR expression ex vivo and in vivo. PLoS One 5: e10682, 2010 [IF=4.4]
  7. Levy E, Lalonde G, Delvin E, Elchebly M, Précourt LP, Seidah N.G., Spahis S, Rabasa-Lhoret R, Ziv E. Intestinal and Hepatic Cholesterol Carriers in Diabetic Psammomys obesus. Endocrinology 151: 958-970, 2010 [5.2]
  8. Dong B., Wu M., Li H., Kraemer F.B., Adeli K., Seidah N.G., Park S.W., and Liu J. Strong Induction of PCSK9 Gene expression through HNF1a  and SREBP2: Mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslypidemic hamsters. J. Lipid Res. 51: 1486-1495, 2010 [IF=4.4]
  9. Mbikay M., Sirois F., Mayne J., Wang G.-S., Chen A., Dewpura T., Prat A., Seidah N.G., Chretien M. and Scott F. Impaired Glucose Tolerance and Pancreatic Islet Abnormalities in PCSK9-Deficient Mice. FEBS Lett. 584: 701-706, 2010 [IF=3.3]
  10. Bryleva E., Rogers M., Chang C., Buen F., Harris B., Rousselet E., Seidah N.G., Oddo S., LaFerla F., Spencer T., Hickey W., Chang T-Y. Gene Ablation Increases 24(S)-Hydroxycholesterol Content in the Brain and Ameliorates Amyloid Pathology in AD Mice. Proc. Natl. Acad. Sci. USA 107: 3081-3086, 2010 [IF=9.6]
  11. Dubuc G., Tremblay M., Paré G., Jacques H., Hamelin J., Benjannet S., Boulet L. , Genest J , Bernier L., Seidah N.G., and Davignon J. A New Method for Measurement of Total Plasma PSCK9 – Clinical Applications. J. Lipid Res. 51: 140-149, 2010 [IF=4.4] 


2009

  1. Sun X., Essalmani R., Seidah N.G., and Prat A. The role of PC5/6 in intestinal tumorigenesis. Mol. Cancer 8: 73-82, 2009 [IF=5.4]
  2. Poirier S., Mayer G., Poupon V., McPherson P.S., Desjardins R., Ly K., Asselin M.-C., Day R., Duclos F.J., Witmer M., Parker R., Prat A. and Seidah N.G. Dissection of the endogenous cellular pathways of PCSK9-induced ldlr degradation: evidence for an intracellular route. J. Biol. Chem. 284: 28856-28864, 2009 [IF=5.8]
  3. Blanchard A., Iwasiow B., Yarmill A., Fresnosa A., Silha J., Myal Y., Murphy L. C., Chrétien M., Seidah N.G., and Shiu R.P.C. Targeted production of proprotein convertase PC1 enhances mammary development and turmorigenesis in transgenic mice. Can. J. Physiol. Pharmacol. 87: 831-838, 2009 [IF=1.7]
  4. Iatan I., Dastani Z., Do R., Weissglas-Volkov D., Ruel I., Lee J.C., Huertas-Vazquez A., Taskinen M-R., Prat A., Seidah N.G., Pajukanta P., Engert J.C., and Genest J. Genetic Variation at the proprotein convertase subtilisin/kexin type 5 Gene modulates HDL cholesterol levels. Circulation: Circ Cardiovasc Genet. 2: 467-475, 2009 [IF=13.5]
  5. Labonté P., Begley S., Guévin C., Asselin M-C., Nassoury N., Mayer G., Prat A., Seidah N.G. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 50: 17-24, 2009 [IF=10.7]
  6. Leblond F., Seidah N.G., Précourt L-P., Delvin E., Dominguez M., and Levy E. Regulation of the proprotein convertase subtilisin/ kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 296: G805-15, 2009 [IF=3.8]
  7. Gorski J.P., Huffman N.T., Henderson E.P., Cui S., Midura R.J.and Seidah N.G. Potential role of proprotein convertase SKI-1 in the mineralization of primary bone. Cells Tissues Organs 189: 25-32, 2009 [IF=2]
  8. Vetrivel K.S., Meckeler X., Chen Y., Nguyen P.D., Seidah N.G., Vasar R., Wong P., Fukata M., Kounnas M.Z., Thinakaran G. Alzheimer disease Ab production in the absence of S-palmitolation dependent targeting of BACE1 to lipids rafts. J. Biol. Chem., 284: 3793-3803, 2009 [IF=5.8]
  9. Seidah N.G., Neuroendocrine Peptide Processing, In: Larry R. Squire, Editor(s)-in-Chief, Encyclopedia of Neuroscience, Academic Press, Oxford, pp. 343-350, 2009
  10. Seidah N.G. PCSK9 as a therapeutic target of dyslipidemia. Expert Opinion Ther. Targets 13: 19-28 2009 [IF=3.3] 


2008 

  1. Labonté P. and Seidah N.G. Emerging viruses: risk of pandemic. Expert Opinion Ther Targets  5: 581-3, 2008 [IF=3.3]
  2. Mayer G., Poirier S., and Seidah N.G. Annexin A2 is a C-terminal PCSK9 binding protein that regulates endogenous LDLR levels. J. Biol. Chem. 283: 31791-801, 2008 [IF=5.8]
  3. Scamuffa N., Basak A., Wargnier A., Marcinkiewicz J., Siegfried G., Chrétien M., Calvo F., Seidah N.G., Khatib A.-M. Regulation of prohepcidin processing and activity by the subtilisin-like pro-protein convertases Furin, PC5, PACE4 and PC7. Gut. 57: 1573-82, 2008 [IF=9]
  4. Chrétien M, Seidah N.G., Basak A, Mbikay M. Proprotein convertases as therapeutic targets. Expert Opinion Ther Targets. 12: 1289-1300, 2008 [IF=3.3]
  5. Ozden S., Lucas-Hourani M., Ceccaldi P.-E., Basak A.,Valentine M., Benjannet S., Hamelin J., Jacob Y., Mamchaoui K., Mouly V., Desprès P., Gessain A., Butler-Brown G., Chretien M., Tangy F., Vidalain P.-O. and  Seidah N.G. Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein. J. Biol. Chem. 283: 21899-21908, 2008 [IF=5.8]
  6. Dewpura T., Raymond A., Hamelin J., Seidah N.G., Mbikay M., Chrétien, M., Mayne J. PCSK9 is Phosphorylated by a Golgi Casein Kinase-Like Kinase ex vivo and Circulates as a Phosphoprotein in Humans. FEBS J. 275 : 3480-3493, 2008 [IF=3]
  7. Szumska D, Pieles G, Essalmani R, Bilski M, Mesnard D, Kaur K., Franklyn A, El Omari K, Jefferis J, Bentham J, Taylor JM, Schneider JE, Arnold SJ, Johnson P, Tymowska-Lalanne Z, Stammers D, Clarke K, Neubauer S, Morris A, Brown SD, Shaw-Smith C, Cama A, Capra V, Ragoussis J, Constam D, Seidah N.G., Prat A and Bhattacharya S: VACTERL/Caudal Regression/Currarino Syndrome like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev. 22: 1465-77, 2008 [IF=15]
  8. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz E., Chamberland A., Hamelin J., Tremblay M., Jacques H., Jin W., Davignon J., Seidah N.G. and Prat A. PCSK9: hepatocyte-specific LDL receptor degradation and critical role in liver regeneration. Hepatology, 48: 646-54, 2008 [IF=10.5]
  9. Xiao Y., Chen G., Richard J., Rougeau N., Li H. Seidah N.G. and Cohen E.A. Cell-surface processing of extracellular human immunodeficiency virus type 1 vpr by proprotein convertases. Virology 372: 384-97, 2008 [IF=3.5]
  10. Essalmani R., Zaid A., Marcinkiewicz J., Chamberland A., Pasquato A., Seidah N.G. and Prat A. In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a major substrate. Proc. Natl. Acad.Sci. USA. 105: 5750-5755, 2008 [IF=9.6]
  11. Seidah N.G., Mayer G., Zaid A., Rousselet E., Nassoury N., Poirier S., Essalmani R. and Prat A. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol. 40: 1111-25, 2008 [IF=4.8]
  12. Pasquato A., Seidah N.G. The H5N1 influenza variant Fujian-like hemagglutinin selected following vaccination exhibits a compromised Furin cleavage - Neurological Consequences of Highly Pathogenic Fujian H5N1 Strains. J Mol Neurosci. 35: 339-43, 2008 [IF=3]
  13. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah N.G., Khatib AM. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest. 118: 352-363, 2008 [IF=15.8]
  14. Poirier S., Mayer G, Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., Mayer H., Nimpf J., Prat A. and Seidah N.G. The Proprotein Convertase PCSK9 Induces the degradation of LDLR and its closest family members VLDLR and apoER2. J Biol Chem. 283: 2363-72, 2008 [IF=5.8]
  15. Mayer G., Hamelin J., Asselin M.-C., Pasquato A., Marcinkiewicz E., Tang M., Tabibzadeh S. and Seidah N.G. The regulated cell-surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates, J. Biol. Chem. 283: 2373-84, 2008 [IF=5.8] 


2007 

  1. Pasquato A., Dettin M., Gambaretto R., Tonin L., Seidah N.G. and Di Bello C. Heparin optimizes the furin cleavage of HIV-1 gp160 peptides. FEBS Lett. 581: 5807-5813, 2007 [IF=3.4]
  2. Lapierre M., Siegfried G., Scamuffa N., Bontemps Y., Calvo F., Seidah N.G., Khatib A-M. Opposing function of the proprotein convertases Furin and PACE4 on breast cancer cells’ malignant phenotypes: Role ofTissue Inhibitors of Metalloproteinase-1. Cancer Research 67: 9030-9034, 2007 [IF=7.7]
  3. Mayne J.E., Raymond A.M., Chaplin A.C., Cousins M., Kaefer N., Gyamera-Acheamponga C., Seidah N.G., Mbikay M., Chrétien M.,.Ooi T.C. Plasma PCSK9 levels correlate with cholesterol in men but not in women Biochemical and Biophys. Res. Commun. 361: 451-456, 2007 [IF=2.9]
  4. Pullikotil P, Benjannet S, Mayne J, Seidah N.G. The proprotein convertase SKI-1/S1P: Alternate translation and subcellular localization. J. Biol. Chem. 282: 27402-27413, 2007 [IF=5.8]
  5. De Windt A., Rai M., Bernier L., Thelen K.M, Soini J., Lefebvre C., Chintawar S., Lavigne J., Nurmi L., Kytömäki L. , Munzer J.S., Lütjohann D., Pandolfo M., Davignon J., Seidah N.G., Laaksonen R. Gene Set Enrichment Analysis reveals several globally affected pathways due to SKI-1/S1P inhibition in HepG2 cells. DNA Cell Biol. 11: 765-772, 2007 [IF=2]
  6. Dikeakos J.D., Mercure C., Lacombe M.-J., Seidah N.G. and Timothy L. Reudelhuber. PC1/3, PC2 and PC5/6A are Targeted to Dense Core Secretory Granules by a Common Mechanism. FEBS J. 16: 4094-4102, 2007 [IF=3]
  7. Mbikay M , Croissandeau G., Sirois F., Anini Y., Mayne J., Seidah N.G., Chretien M. A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission and heterozygous female susceptibility to dietary fat. Dev Biol. 306: 584-598, 2007 [IF=4.9]
  8. Billova S., Seidah N.G., and Kumar, U. Immunohistochemical Expression and Colocalization of Somatostatin, Carboxypeptidase-E and Prohormone convertase PC1 and PC2 in Rat Brain. Neuroscience 147: 403-418, 2007 [IF=3.4]
  9. Nassoury N., Blasiole D., Oler T. A., Benjannet S., Hamelin J., Attie A.D., Prat A., and Seidah N.G. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 6: 718-732, 2007 [IF=6.6]
  10. Mbikay M., Mayne J., Seidah N.G. and Chretien M. of PCSK9, cholesterol homeostasis and parasitic infections: possible survival of loss-of-function PCSK9 polymorphisms (A Hypothesis). Journal of Medical Hypotheses 69: 1010-1017, 2007 [IF=1]
  11. Seidah N.G. and Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85: 685-696, 2007 [IF=5.9]
  12. Goodridge J.P, Lathbury L.J, Steiner N.K , Shulse C.N., Pullikotil P., Seidah N.G., Hurley C.K., Christiansen F.T., Witt C.S. Three Common Alleles of KIR2DL4 (CD158d) Encode Constitutively Expressed, Inducible and Secreted Receptors in NK Cells. Eur J Immunol., 37: 199-211, 2007 [IF=4.8]
  13. Tremblay L.O., Kovács E N., Daniels E., Wong N.K., Sutton-Smith M., Morris H.R., Dell A., E. Marcinkiewicz, Seidah N.G. McKerlie C., and Herscovics A. Respiratory distress and neonatal lethality in mice lacking Golgi 1,2-mannosidase IB involved in N-glycan maturation J. Biol. Chem., 282: 2558-2566, 2007 [IF=5.8] 


2006 

  1. Scamuffa N., Calvo F., Chrétien M., Seidah N.G. , Khatib A-M : Proprotein convertases: Lessons from Knockouts. FASEB J., 12: 1954-63, 2006 [IF=6.8]
  2. Yakovleva T., Marinova Z., Kuzmin A., Seidah N.G. , Haroutunian V., Terenius L., and Bakalkin G: Dysregulation Of Dynorphins In Alzheimer Disease. Neurobiol Aging, 28: 1700-1708, 2006 [IF=5.6]
  3. Benjannet S., Rhainds D., Hamelin J., Nassoury N., and Seidah N.G. The proprotein convertase PCSK9 is inactivated by Furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281: 30561-30572, 2006 [IF=5.8]
  4. Guillemot J., Barbier L., Thouennon E., Vallet-Erdtmann V., Montero-Hadjadje M., Lefebvre H., Klein M., Muresan M., P.-F. Plouin, Seidah N.G. Vaudry H., Anouar Y., and L. Yon: Expression and Processing of the Neuroendocrine Protein Secretogranin-II in Benign and Malignant Pheochromocytomas. Ann. N. Y. Acad. Sci. 1073: 527–532, 2006 [IF=2]
  5. Croissandeau G., Wahnon F., Yashpal K, Seidah N.G., Coderre T.J., Chretien M., Mbikay M. Increased stress-induced analgesia in mice lacking the proneuropeptide convertase PC2. Neurosci. Lett. 406 : 71-75, 2006 [IF=2]
  6. Pasquato A., Pullikotil P., Asselin M-C., Vacatello M., Paolillo L., Ghezzo , Basso F.,Bello C., Dettin M., Seidah N.G. The Proprotein convertase SKI-1/S1P: in vitro analysis of lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors J. Biol. Chem. 281: 23471-23481, 2006 [IF=5.8]
  7. Poirier S., Prat A., Marcinkiewicz E., Paquin J., Baranowski D., Chitramuthu B., Cadieux B., Bennett H.P.J. and Seidah N.G. Implication of the proprotein convertase NARC-1/PCSK9 in neurogenesis. J. Neurochem. 98: 838-850, 2006 [IF=4.3]
  8. Seidah N.G., Khatib A M,, and Prat A. The Proprotein Convertases and their Implication In Sterol and/or Lipid Metabolism. Biol. Chem. 387: 871-877, 2006 [IF=2.8]
  9. Seidah N.G. Unexpected similarity between the cytosolic West Nile Virus NS3 and the secretory Furin-like serine proteinases. Biochem. J. 393: 1-3, 2006 [IF=4]
  10. Essalmani R, Hamelin J, Marcinkiewwicz E, Chamberland A, Mbikay M, Chretien C, Seidah N.G. and Prat A: Genetic deletion of PC 5/6 leads to early embryonic lethalithy. Mol. Cell Biol., 1: 354-361, 2006 [IF=6.8]
All rights reserved: IRCM 2011_110 avenue des Pins Ouest - Montréal (Québec) H2W 1R7 – Canada
.